Trial · Interventional
Not yet recruitingPhase 4Registry dataAssessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery
Overview
- Status
- Not yet recruiting
- Phase
- Phase 4
- Enrollment
- 20 participants (estimated)
- Sponsor
- Chinese University of Hong Kong · Other
- Design
- Allocation not applicable · Open label (no masking)
- Countries
- Not stated
- Start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Oct 2027 (estimated)
- Completion
- 1 Oct 2028 (estimated)
- First posted
- 6 Oct 2026
- Last update posted
- 6 Oct 2026
- Conditions
- Colorectal Cancer · Colorectal Surgery · Ureteric Injury
Timeline
1 trial · 1 not yet recruiting
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
- Ph 4
Assessing the Feasibility of Using Methylene Blue in Identifying Ureters During Colorectal Surgery
NCT07861815est. 1 Oct 2026 to est. 1 Oct 2028
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
This study will assess whether methylene blue fluorescence imaging can help surgeons identify the ureters during colorectal surgery. Methylene blue, given through a vein during the operation, is taken up and excreted by the kidneys, allowing the ureters to appear under a special fluorescence camera system. The study will include adults undergoing open, laparoscopic, or robotic colorectal surgery at Prince of Wales Hospital. The surgeons will compare ureter visibility using standard white light with visibility using fluorescence imaging at different stages of the operation. The study will also assess the best dose of methylene blue, the additional time required, the ease of using the imaging system, and whether the imaging findings affect the surgical plan. The study's hypothesis is that methylene blue fluorescence imaging will make it easier or faster to identify the ureters than white light alone. The technique will be considered feasible if it is helpful in at least 20% of operations-for example, by identifying a ureter earlier or identifying it when it cannot be seen under white light. The findings will help determine whether a larger future study should be conducted.
Interventions
- Intravenous Methylene BlueDrug
- Methylene Blue Fluorescence Imaging SystemDevice
Arms1
Experimental
Methylene Blue Fluorescence Imaging Arm
Intravenous Methylene Blue with Fluorescence Imaging for Ureter Identification
Primary outcomes1
Outcomes the sponsor listed as primary.
Proportion of cases in which fluorescence imaging with methylene blue is deemed helpful for identifying the index ureter
Time frame · Intraoperative - at three predefined stages of the index operation (before dissection, before division of critical structures, and after specimen removal)
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
No results are posted for this trial.
A trial that is still running, or that stopped early, may post results later.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies0
Studies that cite this trial.
No study cites this trial.
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- from 18 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
PepBank is a research reference. Talk to a doctor before you use any peptide.